Sinovac says COVID-19 vaccine 100% effective in preventing hospitalization, death

China’s Sinovac Biotech on said late-stage trial data of its COVID-19 vaccine from Brazil and Turkey showed it prevented hospitalization and death in COVID-19 patients, but had a much lower efficacy rate in blocking infections, SİA reports citing Reuters.

The 12,396-person trial found the CoronaVac vaccine was 100% effective in preventing COVID-19 sufferers from being hospitalized or dying and 83.7% effective in avoiding cases that required any medical treatment, but only 50.65% effective at keeping people from getting infected, according to a statement.

The trials evaluated the efficacy of the two-shot vaccine candidate 14 days after inoculation of participants, including healthcare workers who treat COVID-19 patients.

In Turkey, the vaccine was tested in two stages among health care workers and the general population, and found to have a 91.25% efficacy rate in preventing COVID-19 based on an analysis of 29 cases, the company said.

In early January this year, Brazilian researchers reported interim results from the CoronaVac vaccine trial showing it was 50.4% effective at preventing symptomatic infections.

Efficacy rates of other vaccines have varied widely by country, an emerging pattern reflecting the impact of new variants.

Bütün xəbərlər Facebook səhifəmizdə